SCHEMBL1092697

SCHEMBL1092697

CC(C)[Si](OC1CCN(N2CCC(Cc3c(Cl)cc(OCc4ccccc4)cc3Cl)C2=O)CC1)(C(C)C)C(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 2/20 0.37
MCHR1 Q99705 1/20 0.36
S1PR1 P21453 1/20 0.35
PRKX P51817 1/20 0.35
ACVR1 Q04771 1/20 0.35
S1PR5 Q9H228 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
LMNA P02545 2/20 0.35
HRH3 Q9Y5N1 3/20 0.34
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
CREBBP Q92793 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
NOX4 Q9NPH5 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1092695 1.00 FDFT1 (0.37) FDFT1MCHR1S1PR1PRKXACVR1
SCHEMBL210842 0.86 HSD11B1 (0.43) FDFT1MCHR1S1PR1PRKXACVR1
SCHEMBL210841 0.86 HSD11B1 (0.43) FDFT1MCHR1S1PR1PRKXACVR1
SCHEMBL210843 0.86 HSD11B1 (0.43) FDFT1MCHR1S1PR1PRKXACVR1
SCHEMBL1091787 0.85
SCHEMBL1091788 0.85
SCHEMBL1092839 0.84 NPC1 (0.49) FDFT1MCHR1S1PR1PRKXACVR1
SCHEMBL1092836 0.84 NPC1 (0.49) FDFT1MCHR1S1PR1PRKXACVR1
SCHEMBL1091967 0.82 DRD2 (0.31)
SCHEMBL1093100 0.82 DRD2 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153807-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-04-10 US disclosed
EP-2021336-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-30 EP disclosed
US-20090111809-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 BUSH JULIE KAY 2009-04-30 US disclosed
EP-2021336-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-02-11 EP disclosed
WO-2007127688-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111809-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD3B1, HSD11B2 FDFT1 68/4885MCHR1 1624/4885S1PR1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.